Evosep webinar
Evosep Eno: A New Era of Speed, Scale and Robustness
Available on demand
Missed the big launch at ASMS 2025? We’ve got you covered. Join this session to get the full story and discover how Evosep Eno simplifies workflows and supports labs of all sizes.
The Evosep Eno represents a significant leap forward in proteomics technology — delivering the speed, precision, and reproducibility needed to transform drug discovery and translational research.
SPEAKERSÂ
Talk by Tim HeymannMass Spectrometry Specialist at Max Planck Institute of Biochemistry
Ultra-fast proteomics: Evosep ENO and Orbitrap Astral Zoom MS combo enables ultra-fast proteome profiling with high proteome coverage and reproducibility
Talk by Ulises Hernández-Guzmán, Assistant Research Scientist at Novo Nordisk Foundation Center for Protein Research, University of Copenhagen
High-throughput proteomics plays a vital role in elucidating biological systems, facilitating large-scale initiatives such as biomarker discovery and systems biology. Despite recent advancements in hardware hardware sofware, existing mass spectrometry (MS) technologies encounter challenges in speed, sensitivity, and scalability when analyzing extensive sample cohorts. To overcome these limitations, the Orbitrap Astral Zoom mass spectrometer has been developed, significantly enhancing acquisition speed, ion utilization, and proteome depth. This innovative MS achieves ultra-fast MS/MS scan rates of up to 270 Hz through improved ion pre-accumulation. To fully leverage the potential of Astral Zoom MS it is essential co couple it with a robust LC system such Evosep Eno, which combined with Astral Zoom enables ultra-high-throughput workflows, identifying over 7,000 proteins in a 500 SPD method with exceptional reproducibility (Pearson correlation >0.99). The Orbitrap Astral Zoom interfaced with the new Evosep ENO establishes a new standard in proteomics, substantially improving speed, sensitivity, and scalability, thus enabling routine large-scale proteome studies with significant implications for clinical and systems biology applications.
